Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2/3 1Phase 2 1

Status

Completed 3Recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Conditions

Myasthenia Gravis 6

Interventions

rozanolixizumab 7zilucoplan 6efgartigimod alfa 5eculizumab 4telitacicept 3ravulizumab 3Tacrolimus 3Rituximab 3Amifampridine 3Prednisone 2Mycophenolic Acid 2HBM9161 2satralizumab 1remibrutinib 1iptacopan 1inebilizumab 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisolone 1Plasmapheresis 1Leflunomide 1Immunoglobulins, Intravenous 1Hizentra 1Cladribine 1Azathioprine 1Alkalies 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Myasthenia Gravis × zilucoplan × Clear all
NCT06435312 2026-05-08

ziMyG+

UCB Pharma

Phase 3 Enrolling by invitation
8 enrolled

Myasthenia Gravis

NCT04225871 2026-04-24

RAISE-XT

UCB Pharma

Phase 3 Active not recruiting
200 enrolled

Myasthenia Gravis

NCT06471361 2026-03-27

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
31 enrolled 11 charts

Myasthenia Gravis

NCT07215949 2026-02-23

Zilucoplan for Severe gMG Exacerbations

Ohio State University

Phase 3 Recruiting
15 enrolled

Myasthenia Gravis

NCT05514873 2025-09-03

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

UCB Pharma

Phase 3 Completed
26 enrolled 14 charts

Myasthenia Gravis

NCT04115293 2025-07-16

RAISE

UCB Pharma

Phase 3 Completed
174 enrolled 19 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡